Clinical trials: Myelodysplastic Neoplasm
Leukemia, Lymphoma
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about diagnosing cancer and determine a patient's eligibility for a treatment…
- Trial name
- NCT00897767
- Testing
- biologic sample preservation procedure
- Where
- 214 sites in United States
- Volunteers
- 1,873 people
- Sponsor
- Eastern Cooperative Oncology Group
MDS
A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS
This is an open-label, phase 1b study to evaluate the safety, tolerability and preliminary efficacy of IBI188 in combination with Azacitidine in newly diagnosed higher risk MDS patients.
- Trial name
- NCT04511975
- Testing
- IBI188, Azacitidine
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Bone Marrow Transplantation, Blood Disease
Blood and Marrow Transplant Clinical Research Network
The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.
- Conditions
- Bone Marrow Transplantation, Blood Disease, Hematopoietic Stem Cell Transplantation, Leukemia
- Trial name
- NCT00023530
- Testing
- fluconazole, voriconazole, bone marrow transplant
- Where
- 16 sites in United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.
- Trial name
- NCT07128381
- Testing
- Axatilimab (SNDX-6352), Ruxolitinib
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies
The primary purpose of this study is to evaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies including refractory acute leukemia.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00270881
- Testing
- Cord blood transplantation, TBI, cyclophosphamide
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Keio University
MDS
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
This study is a phase Ib add-on study of the combination of LDE255 to azacitidine in patients without marrow response after at least 6 cycles of azacitidine.
- Trial name
- LDE255 (NCT02323139)
- Testing
- Azacitidine and LDE255
- Where
- 24 sites in France
- Volunteers
- 23 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Myelodysplastic Syndrome, MDS
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
The purpose of this research is to evaluate the use of lenalidomide and prednisone in people with Myelodysplastic Syndrome (MDS).
- Trial name
- NCT01133275
- Testing
- Prednisone, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Chronic Myeloproliferative Disorders, Leukemia
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of decitabine and FR901228 in treating patients with relapsed or refractory leukemia, myelodysplastic syndromes or myeloproliferative disorders.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00114257
- Testing
- decitabine, romidepsin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes
AVIDA The Vidaza® (Azacitidine) Patient Registry
This registry is a prospective, multi-center, observational study compiling data on the natural history and management of patients receiving Vidaza, and will provide unique insights into the management of myelodysplastic…
- Trial name
- AVIDA (NCT00481273)
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 479 people
- Sponsor
- Celgene
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
- Trial name
- NCT03735446
- Testing
- Prexasertib, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005946
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with azacitidine.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01110473
- Testing
- ABT-348, ABT-348 and azacitidine
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Leukemia
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with azacitidine to patients with MDS or AML.
- Trial name
- NCT01038635
- Testing
- 5-Azacytidine, Lenalidomide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Trial name
- NCT01929408
- Where
- 12 sites in United States
- Volunteers
- 703 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: A donor stem cell transplant can lower the body's immune system, making it difficult to fight off infection. Giving antibiotics, such as moxifloxacin, may help prevent bacterial infections in patients who have recently…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00324324
- Testing
- moxifloxacin hydrochloride
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- OHSU Knight Cancer Institute
Myelodysplastic Syndromes
Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China
The purpose of this study is to evaluate the treatment patterns and clinical outcomes in adults with lower-risk MDS (LR-MDS) who were erythropoiesis-stimulating agents (ESA)-naïve and received luspatercept treatment in China
- Trial name
- NCT07073690
- Testing
- Luspatercept
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Bristol-Myers Squibb
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
This trial tests the safety, side effects, and best dose of navitoclax in combination with venetoclax and decitabine in treating patients with higher risk myelodysplastic syndrome (MDS) that has come back after initial treatment…
- Conditions
- Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
- Trial name
- NCT05564650
- Testing
- Navitoclax, Venetoclax, Decitabine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Thomas Jefferson University
Myelodysplastic Syndrome
The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome
The purpose of this study is determine whether combination Q10 , L-carnitine and multivitamin and mineral complex is effective in treatment of patients with low and intermidiate1-2 risk Myelodysplastic syndrome
- Trial name
- NCT02042482
- Testing
- Coenzyme Q10U, L-carnitine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Kaplan Medical Center
Myelodysplastic Syndromes, Blood Disease
Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
This study is to evaluate the efficacy, safety and tolerability of vorinostat in patients with lower risk Myelodysplastic Syndrome (MDS).
- Conditions
- Myelodysplastic Syndromes, Blood Disease, Bone Marrow Disease
- Trial name
- NCT00486720
- Testing
- vorinostat
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.